15/09/2024

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

15/09/2024

Sep 15, 2024, 23:34 | Insight
Insights from ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 15, 2024, 23:21 | Blog
MD Anderson and Rice launch initiative to advance cancer-focused operations research
The University of Texas MD Anderson Cancer Center and Rice University announced the launch of…
Sep 15, 2024, 16:37 | Dialogues
Addressing Global Breast Cancer Disparities with Vicki Durston v2 | United Against Cancer
In this episode of United Against Cancer, Vicki Durston, Director of Policy and Advocacy at…
Sep 15, 2024, 16:36 | Blog
Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer
Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak…
Sep 15, 2024, 16:36 | Blog
Gaza’s Cancer Patients: Navigating the dual struggle of illness and war
At the 28th World Cancer Conference in Geneva, Switzerland, healthcare professionals focused on the challenges…
Sep 15, 2024, 16:26 | Societies
43 Posts Not To Miss From ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 15, 2024, 16:06 | Blog
Joaquim Bellmunt: The role of mTORC1/2 inhibitor sapanisertib
Petros Grivas shared an article by Joaquim Bellmunt on X: "Congrats Joaquim Bellmunt and your team…
Sep 15, 2024, 15:58 | Blog
OncoInfluencers to Follow on Social Media: Dr. Neeraj Agarwal
We are delighted to feature Dr. Neeraj Agarwal as a key figure in the oncology…
Sep 15, 2024, 15:21 | Blog
Addressing Global Breast Cancer Disparities with Vicki Durston v1 | United Against Cancer
In this episode of United Against Cancer, Vicki Durston, Director of Policy and Advocacy at…
Sep 15, 2024, 15:20 | Insight
Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar…
All: 46 Posts: 1 - 10
Special Coverage